You have 9 free searches left this month | to do more

Atezolizumab

Atezolizumab is a drug used to treat Breast Cancer, Non-Small Cell Lung Cancer, Urothelial Carcinoma, and other conditions. Atezolizumab is being actively studied in 327 studies and prior, has been studied in 42.

Top SponsorsTop SitesTop Investigators
Hoffmann-La RocheAsan Medical CenterAslaug Helland
National Cancer Institute (NCI)Seoul National University HospitalDwight Owen
Genentech, Inc.Samsung Medical CenterGulam Manji
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
T
Neoadjuvant Atezolizumab in Cutaneous Melanoma
Recruiting
  • Cutaneous Melanoma
  • Atezolizumab
  • Houston, Texas
    Houston Methodist Hospital
2021-12-28
Dec 28, 2021
W
Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection
Not yet recruiting
  • Stage II Melanoma
  • Atezolizumab
  • +2 more
  • Duarte, California
  • +5 more
2022-03-15
Mar 15, 2022
H
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
Recruiting
  • Rectal Neoplasms
  • Rectal Cancer
  • Radiotherapy
  • +4 more
  • Shanghai, China
    Zhongshan Hospital Fudan University
2022-03-28
Mar 28, 2022
I
Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements
Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Bad Saarow, Germany
    HELIOS KLinikum Bad Saarow
2022-03-29
Mar 29, 2022
D
Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis
Active, not recruiting
  • Breast Cancer
  • Atezolizumab
  • Stereotactic radiosurgery (SRS)
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
2021-12-27
Dec 27, 2021
M
Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
Not yet recruiting
  • Solid Tumor
  • Atezolizumab
  • +3 more
  • Dallas, Texas
    The University of Texas Southwestern Medical Center
2022-03-29
Mar 29, 2022
S
Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma
Recruiting
  • Cutaneous Squamous Cell Carcinoma
  • Atezolizumab
  • Stanford, California
    Stanford University
2021-06-30
Jun 30, 2021
M
SBRT + Atezolizumab + Bevacizumab in Resectable HCC
Recruiting
  • Hepatocellular Carcinoma
  • Resectable Hepatocellular Carcinoma
  • Atezolizumab
  • +2 more
  • Boston, Massachusetts
    Massachusetts General Hospital Cancer Center
2022-02-10
Feb 10, 2022
G
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
Recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • Washington, District of Columbia
    MedStar Georgetown University Hospital
2022-02-25
Feb 25, 2022
U
Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer
Active, not recruiting
  • Cervical Cancer
  • Leuven, Belgium
    UZLeuven
2021-01-26
Jan 26, 2021
M
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
Not yet recruiting
  • Recurrent Glioblastoma
  • Recurrent Gliosarcoma
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-31
Mar 31, 2022
D
Abemaciclib With or Without Atezolizumab for mCRPC
Recruiting
  • Prostate Cancer
  • Metastatic Castration-resistant Prostate Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2021-09-20
Sep 20, 2021
H
SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma
Recruiting
  • Hepatocellular Carcinoma
  • Selinexor Pill
  • +2 more
  • Tampa, Florida
    Moffitt Cancer Center
2022-03-23
Mar 23, 2022
W
Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Recruiting
  • Extensive-stage Small Cell Lung Cancer
  • Saint Louis, Missouri
    Washington University School of Medicine
2021-12-09
Dec 9, 2021
U
Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).
Not yet recruiting
  • Squamous Cell Carcinoma
  • Urinary Tract Cancer
  • Atezolizumab
  • (no location specified)
2021-09-07
Sep 7, 2021
T
AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer
Active, not recruiting
  • Breast Cancer
  • Amsterdam, Netherlands
  • +3 more
2022-03-21
Mar 21, 2022
U
Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN
Recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • Atezolizumab
  • Essen, Germany
    University Hospital Essen
2021-10-06
Oct 6, 2021
H
Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
Active, not recruiting
  • Melanoma
  • Beijing City, China
  • +2 more
2022-04-07
Apr 7, 2022
N
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
Active, not recruiting
  • HER2-positive Metastatic Breast Cancer
  • Central Nervous System Metastases
  • ATEZOLIZUMAB
  • +2 more
  • Chicago, Illinois
  • +1 more
2022-03-14
Mar 14, 2022
G
Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab
Recruiting
  • Locally Advanced Cervical Cancer
  • Atezolizumab
  • +2 more
  • Villejuif, Val De Marne, France
    Gustave Roussy
2022-02-15
Feb 15, 2022
A
Atezolizumab With/Without IMM-101 in Patients With MSI-h/MMR-D Stage III Colorectal Cancer Ineligible for Oxaliplatin
Recruiting
  • Colorectal Cancer
  • Atezolizumab
  • Essen, Germany
    Westdeutsches Tumorzentrum
2022-02-14
Feb 14, 2022
M
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
Not yet recruiting
  • Locally Advanced Osteosarcoma
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-25
Feb 25, 2022
I
A Trial of Ipatasertib in Combination With Atezolizumab
Recruiting
  • Solid Tumor
  • +2 more
  • Sutton, Surrey, United Kingdom
    Royal Marsden Hospital NHS Foundation Trust
2022-03-31
Mar 31, 2022
N
Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC
Recruiting
  • Small Cell Lung Cancer Recurrent
  • Atezolizumab
  • Goyang-si, Gyeonggi-do, Korea, Republic of
    National Cancer Center
2022-04-04
Apr 4, 2022
U
Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
Not yet recruiting
  • NSCLC Stage IV
  • NSCLC, Recurrent
  • Atezolizumab
  • Fairway, Kansas
  • +1 more
2022-01-20
Jan 20, 2022